Alkermes is positioned for outperformance due to its conservative cash-heavy balance sheet and high-margin business model.

Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise ...

Throughout the last three months, 7 analysts have evaluated Alkermes (NASDAQ:ALKS), offering a diverse set of opinions from ...

Alkermes plc ALKS has made steady progress with its portfolio of proprietary products — Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia) and Lybalvi (schizophrenia and bipolar ...

Alkermes plc ALKS reported adjusted earnings from continuing operations of 44 cents per share for first-quarter 2024, which ...

DUBLIN, April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 ...

"Each year, the spring scientific meetings bring together critical stakeholders from across the field of psychiatry to share insights and advance patient care; Alkermes is honored to have our research ...

Alkermes plc ALKS has made steady progress with its portfolio of proprietary products — Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia) and Lybalvi (schizophrenia and bipolar ...

Alkermes plc ALKS reported adjusted earnings from continuing operations of 44 cents per share for first-quarter 2024, which missed the Zacks Consensus Estimate of 59 cents. The company had ...

DUBLIN (AP) — DUBLIN (AP) — Alkermes PLC (ALKS) on Wednesday reported first-quarter net income of $36.8 million, after reporting a loss in the same period a year earlier. The Dublin-based ...